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Abstract The antiestrogenic effect of tamoxifen is
mainly attributable to the active metabolites endoxifen and
4-hydroxytamoxifen. This effect is assumed to be con-
centration-dependent and therefore quantitative analysis of
tamoxifen and metabolites for clinical studies and thera-
peutic drug monitoring is increasing. We investigated the
large discrepancies in reported mean endoxifen and 4-hy-
droxytamoxifen concentrations. Two published LC–MS/
MS methods are used to analyse a set of 75 serum samples
from patients treated with tamoxifen. The method from
Teunissen et al. (J Chrom B, 879:1677–1685, 2011) sepa-
rates endoxifen and 4-hydroxytamoxifen from other
tamoxifen metabolites with similar masses and fragmen-
tation patterns. The second method, published by Gjerde
et al. (J Chrom A, 1082:6–14, 2005) however lacks
selectivity, resulting in a factor 2–3 overestimation of the
endoxifen and 4-hydroxytamoxifen levels, respectively.
We emphasize the use of highly selective LC–MS/MS
methods for the quantiﬁcation of tamoxifen and its
metabolites in biological samples.
Keywords Tamoxifen Endoxifen 4-Hydroxytamoxifen 
Metabolite levels   LC–MS/MS analysis
Introduction
Tamoxifen is widely administered in the treatment and
chemoprevention of estrogen receptor positive breast can-
cer, which accounts for about 60–70% of all breast cancers
[1–3]. Tamoxifen is considered to be a prodrug that is
converted into many metabolites. The most therapeutically
active metabolites are N-desmethyl-4-hydroxytamoxifen
(endoxifen) and 4-hydroxytamoxifen, being 30- to 100-fold
more potent than tamoxifen itself. The antiestrogenic
activities of endoxifen and 4-hydroxytamoxifen are similar,
although endoxifen, unlike 4-hydroxytamoxifen, is also a
potent inhibitor of aromatase and is present at a higher
steady state concentration in patients than 4-hydroxytam-
oxifen [4–7].
The steady state levels of the active tamoxifen metab-
olites are proposed predictors of the clinical outcomes of
tamoxifen treatment; it is suggested that there is a mini-
mum concentration threshold above which endoxifen is
effective against the recurrence of breast cancer. [8]I ti s
well known from the literature that there is a considerable
inter-patient variability in steady state levels of tamoxifen
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DOI 10.1007/s10549-012-2000-1and its metabolites [5, 8–10]. However, the mean levels
reported by recent studies [8, 10–14], that all included
patients using 20 mg tamoxifen per day and analysed
patient samples with liquid chromatography–tandem mass
spectrometry (LC–MS/MS), differ more than expected
purely based on the inter-patient variability. Three of these
studies report mean endoxifen concentrations between 7.10
and 14.5 ng/mL and mean 4-hydroxytamoxifen levels
between 1.55 and 2.25 ng/mL [9–11], similar to the levels
we ﬁnd in our laboratory, whereas another recent study
reports concentrations twice as high [14]. Two studies from
Norway, both using the LC–MS/MS assay developed by
Gjerde et al. [15], report even higher concentrations;
median concentrations of around 50 ng/mL for endoxifen
and around 5.75 ng/mL for 4-hydroxytamoxifen [12, 13].
In this article we describe the investigation of these
discrepancies, by analysing a set of 75 patient samples with
the assay published by Gjerde et al. [15] and with an assay
developed in our laboratory [16].
Methods
Patient samples
Serum samples were obtained in the period between
December 2010 and September 2011 from patients treated
with tamoxifen in the Netherlands Cancer Institute,
Amsterdam, the Netherlands. The samples were collected
in serum gel tubes and blood was allowed to coagulate for
30 min at room temperature. After coagulation, serum gel
tubes were centrifuged for 10 min at 2,500–3,000 g (tem-
perature was allowed to range from 4C to ambient tem-
perature). Serum was transferred into polypropylene tubes,
which were stored at -70C until the time of analysis.
Extraction and measurement of tamoxifen
and metabolites
Tamoxifen and its metabolites were analysed in 75 patient
samples. All patient samples, 20 calibration standards and
6 quality control samples were handled according to the
method described by Teunissen et al. [16]. A volume of
50 lL human serum was processed. Sample pre-treatment
involved protein precipitation with acetonitrile. After
mixing, samples were centrifuged and the clear superna-
tant was evaporated to dryness under a gentle stream of
nitrogen (30C). The extracts were reconstituted in ace-
tonitrile—4 mM ammonium formate buffer pH 3.5
(3:7 v/v). The ﬁnal extracts were analysed by two dif-
ferent LC–MS/MS assays, method 1 from Teunissen et al.
[16] and method 2 from Gjerde et al. [15], during con-
secutive days.
Method 1
Theassayforthedeterminationoftamoxifen(5–500 ng/mL),
N-desmethyltamoxifen (10–1,000 ng/mL), (E)-endoxifen
(1–100 ng/mL), (Z)-endoxifen (1–100 ng/mL), N-desmeth-
yl-40-hydroxytamoxifen (1–100 ng/mL), 4-hydroxytamoxi-
fen (0.4–40 ng/mL) and 40-hydroxytamoxifen (0.4–40 ng/
mL), from Teunissen et al. [16] was used with slight modi-
ﬁcations. A volume of 5 lL of the ﬁnal extract was injected
onto a Kinetex C18 100 A ˚ column (100 9 4.6 mm ID) and
detection was performed on a triple-quadrupole MS/MS
detectorwithanelectrosprayionizationsource(API4000,AB
Sciex, Foster City, USA) operating in the positive ion mode.
A partial validation was executed and all requirements for
acceptance, as deﬁned in the FDA and EMA guidelines on
Bioanalytical Method Validation [17, 18] were fulﬁlled.
Method 2
The assay for the determination of tamoxifen (5–500 ng/
mL), N-desmethyltamoxifen (10–1000 ng/mL), endoxifen
(1–100 ng/mL), and 4-hydroxytamoxifen (0.4–40 ng/mL)
from Gjerde et al. [15] was used.
Online extraction was not executed in order to analyse
the identical ﬁnal extracts that were used when method 1
was applied. The ﬂow rate was set at 0.8 mL/min, to obtain
comparable retention times.
A volume of 5 lL of each sample was injected onto a
Chromolith Performance RP 18-e column (100 9 4.6 mm
ID) and a gradient elution similar to the separation mode of
the method used by Gjerde et al. was applied. The sepa-
ration was performed at room temperature and the auto-
sampler was thermostatted at 7C. Detection was
performed on a triple-quadrupole MS/MS detector with an
electrospray ionization source (API4000, AB Sciex, Foster
City, USA) operating in the positive ion mode.
Quantiﬁcation of tamoxifen and metabolites
Tamoxifen, N-desmethyltamoxifen-HCl, N-desmethyl-4-
hydroxytamoxifen (endoxifen, E/Z mixture 1:1), N-desm-
ethyl-40-hydroxytamoxifen, 4-hydroxytamoxifen, 40-hydroxy
tamoxifen, tamoxifen-N-oxide, tamoxifen-d5, N-desmethyl-
tamoxifen-d5, N-desmethyl-4-hydroxytamoxifen-d5 (endoxi-
fen-d5, E/Z mixture 1:1) and 4-hydroxytamoxifen-d5 were
purchased from Toronto Research Chemicals (North York,
ON, Canada). The chemical structures of the analytes are
s h o w ni nT a b l e1. Characterization of the peaks in patient
samples was based on comparison with the retention times and
MSfragmentationpatternsofthereferencestandards.Whenno
reference standard was available, identiﬁcation was based on
MS fragmentation and data foundin the literature [10,19].The
reference standard of endoxifen was a racemic mixture (1:1),
794 Breast Cancer Res Treat (2012) 133:793–798
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123resulting in baseline separated peaks when using method 1, but
in a single peak when using method 2. For the quantiﬁcation of
(Z)-endoxifen in patient samples analysed with method 2, the
analyte peak area of the calibration standards and quality con-
trol samples was divided by a factor 2.
Multiple reaction monitoring chromatograms were
acquired at unit resolution (0.7 Da) for quantiﬁcation.
Results and discussion
There are large differences in reported mean steady-state
concentrations of the therapeutically active tamoxifen
metabolites, endoxifen and 4-hydroxytamoxifen. These
discrepancies can only partly be assigned to inter-patient
variability in the biotransformation of tamoxifen. For this
article, we investigated the bioanalytical variability, by
analysing a set of 75 patient samples with two different
LC–MS/MS methods; method 1 from Teunissen et al. [16]
and method 2 from Gjerde et al. [15]. The bioanalytical
data were accepted for both methods, since the back-cal-
culated concentrations of the calibration standards and
quality control samples were all within ±15%. The results
are presented in Table 2.
Tamoxifen and N-desmethyltamoxifen
The measured concentration of tamoxifen and N-desm-
ethyltamoxifen in each serum sample was very similar for
both methods (Fig. 2), resulting in comparable mean con-
centrations (Table 2). There are no tamoxifen metabolites
described in the literature [6, 20] that have molecular
masses similar to tamoxifen or N-desmethyltamoxifen,
therefore co-elution of tamoxifen analogues with frag-
mentation patterns similar to tamoxifen or N-desmethyl-
tamoxifen is not expected.
Endoxifen (m/z 374 ? 58)
There are several metabolites with close resemblance in
molecular structure to endoxifen (Table 1). These com-
pounds also have similar molecular masses and fragmen-
tation patterns, making chromatographic separation of
crucial importance for selective analysis.
The chromatogram obtained with the method from Te-
unissen et al. [16] (Fig. 1a) shows separate peaks for the
metabolites with mass transition 374/58, whereas the
Table 2 Mean concentrations of tamoxifen and three of its metab-
olites analysed with the two described methods, from serum samples
of 75 patients treated with tamoxifen
Mean concentration (ng/mL)
Analyte Method 1
[16] ± s.d.
Method 2 [15]
± s.d.
Tamoxifen 99.7 ± 39.3 103.3 ± 40.4
N-desmethyltamoxifen 184.0 ± 74.7 187.1 ± 77.9
Endoxifen 9.0 ± 4.5 18.1 ± 6.4
4-Hydroxytamoxifen 1.7 ± 0.7 4.6 ± 1.7
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Fig. 1 Representative LC–MS/MS chromatograms obtained from a
study patient sample. Chromatograms a and b were obtained with method
1, from Teunissen et al. [16], and method 2, from Gjerde et al. [15],
respectively, when m/z 374 ? 58 was monitored. Chromatograms c and
d were obtained with method 1 and 2, respectively, when m/z 388 ? 72
was monitored Peak numbers correspond with metabolite numbers in
Table 1
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123chromatogram obtained with the method from Gjerde et al.
[15] (Fig. 1b) shows only a single peak, consisting of N-
desmethyl-a-hydroxytamoxifen, endoxifen, N-desmethyl-
3-hydroxytamoxifen and N-desmethyl-40-hydroxytamoxi-
fen eluting at the same retention time. This lack of selec-
tivity leads to a consequent overestimation of the endoxifen
level of around a factor 2 (Fig. 2; Table 2). Furthermore,
method 1 separates (E)-endoxifen from the therapeutically
active (Z)-endoxifen, whereas method 2 does not separate
these isoforms. However, for all 75 patient samples the (E)-
endoxifen level was below the lower limit of quantitation
(1.0 ng/mL), which is in agreement with the literature [10,
19].
4-Hydroxytamoxifen (m/z 388 ? 72)
As shown in Table 1, there are at least seven tamoxifen
metabolites with masses and fragmentation patterns simi-
lar to 4-hydroxytamoxifen. From these metabolites, the
levels of b-hydroxytamoxifen, 2-hydroxytamoxifen and
1,2-epoxytamoxifen are below the lower limit of detection
(LLOD) of current LC–MS platforms (±0.05 ng/mL) [11,
20]. The chromatogram obtained with method 1 (Fig. 1c)
shows separate peaks for the other four metabolites with
mass transition 388/72, whereas the chromatogram
obtained with method 2 (Fig. 1d) shows only two sepa-
rated peaks. Tamoxifen-N-oxide elutes at 3.06 min and a-
hydroxytamoxifen, 4-hydroxytamoxifen, 3-hydroxytam-
oxifen and 40-hydroxytamoxifen are co-eluting at
2.84 min. This co-elution leads to a consequent overesti-
mation of the 4-hydroxytamoxifen levels of around a
factor 3 (Fig. 2) and therefore the mean 4-hydroxytam-
oxifen concentration obtained with method 2 is a factor 3
higher (Table 2).
The results obtained with method 1 are in good agree-
ment with the levels reported by three recent published
studies. The analytical methods used in these studies all
separated endoxifen and 4-hydroxytamoxifen from com-
pounds with similar masses and fragmentation patterns
[8, 10, 11].
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Fig. 2 Ratio of the measured concentrations obtained with method 1,
C1, and method 2, C2, in 75 patient samples for tamoxifen (a), N-
desmethyltamoxifen(b),(Z)-endoxifen(c)and4-hydroxytamoxifen(d).
The solid line represents a ratio of 1.0 (i.e. equal measured concentra-
tions)andthedottedlinesrepresentthe(bioanalyticallyaccepted)±15%
deviation from method 2 in comparison with method 1
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123When investigating correlations between the levels of
the active tamoxifen metabolites and efﬁcacy and toxicity
parameters, it is crucial to distinguish between the active
metabolites and the 40-hydroxylated metabolites, which are
about ten times less active than 4-hydroxytamoxifen and
endoxifen. [10, 11] Also, for therapeutic drug monitoring
based on reaching a sufﬁcient endoxifen level, it is
important to use a highly selective analysis in order to
accurately quantify endoxifen in the patient sample.
Conclusions
This article demonstrates that high selectivity is of major
importance for the analysis of tamoxifen metabolites, some
of which show marked resemblance in molecular structure
and have similar masses and fragmentation patterns. Lack
of high selectivity results in an overestimation of the
concentration of the therapeutically active metabolites,
endoxifen and 4-hydroxytamoxifen, in patient samples.
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